本文へ移動
サインイン

企業

Actinium Pharmaceuticals

構造マップを開く

Actinium Pharmaceuticals の構造

Actinium Pharmaceuticals

企業

関連 10 件
上流供給と依存
自社製品と技術
下流顧客
同業競合と提携
制約規制とエクスポージャー
関係の開始2026
Actinium Pharmaceuticals企業 · 関連 10 件
第 1 層

上流供給と依存5

下流顧客1

同業競合と提携1

自社製品と技術1

制約規制とエクスポージャー2

関係ネットワークでの位置

118934 件中 2180 位上位 2%今週 5605 位上昇

直接の関係 10 件

密接につながる 451 件のグループに属し、中心は

今週新たに加わった関係

根拠のある公開の関係から毎日計算しています。

関係

矢印は関係の方向を示します。分野で絞り込めます。

  • Actinium Pharmaceuticalsと提携 →National Cancer Institute
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-10-17 05:00
      Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI)
      出典を見る
    • 企業開示PR Newswire news releases2026-10-16 19:30
      Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI)
      出典を見る
    • 企業開示PR Newswire news releases2026-10-16 19:30
      with additional development ongoing through a CRADA with the NCI.
      出典を見る
    • 企業開示PR Newswire news releases2026-10-15 19:30
      Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI)
      出典を見る
  • Sean Maenpaaの一部 →Actinium Pharmaceuticals
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-10-16 19:30
      announced the appointment of Sean Maenpaa as Senior Vice President, Business Development
      出典を見る
  • Actinium Pharmaceuticals規制エクスポージャー →Securities and Exchange Commission
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-10-17 05:00
      risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC")
      出典を見る
  • Actinium Pharmaceuticals需要エクスポージャー →Actinium's products and services
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-10-17 05:00
      the market demand for and acceptance of Actinium's products and services
      出典を見る
  • Actinium Pharmaceuticalsを使用 →HER3
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-11-17 20:00
      Actinium announced HER3, an antigen distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400
      出典を見る
  • Actinium Pharmaceuticalsを使用 →Iomab-ACT
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-11-17 20:00
      Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.
      出典を見る
  • Actinium Pharmaceuticalsを使用 →Positron emission tomography
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-11-17 20:00
      Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.
      出典を見る
  • Actinium Pharmaceuticalsを使用 →Actimab-A
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-11-17 20:00
      Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.
      出典を見る

10 件中 1 から 8 件を表示

主張

出典とともに結論を確認し、項目を開いて証拠を読めます。

事実根拠 3
規制エクスポージャーFDA

These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from anticipated or estimated future results, including risks and uncertainties associated with the conduct, timing and r…

PR Newswire news releases · 2026-11-17 20:00

証拠を見る
  • 企業開示PR Newswire news releases2026-11-17 20:00
    These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from anticipated or estimated future results, including risks and uncertainties associated with the conduct, timing and r…
    出典を見る
  • 企業開示PR Newswire news releases2026-10-17 05:00
    actions by the FDA and other governmental agencies
    出典を見る
  • 企業開示PR Newswire news releases2026-10-16 19:30
    risks and uncertainties associated with the Company's ability to retain key personnel, the Company's ability to identify, negotiate and complete business development, partnering, licensing or other strategic transactions on favorable terms or at all, estimates of potential marke…
    出典を見る
事実根拠 1

Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.

PR Newswire news releases · 2026-11-17 20:00

証拠を見る
  • 企業開示PR Newswire news releases2026-11-17 20:00
    Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.
    出典を見る
事実根拠 2
を使用ATNM-400

Actinium announced HER3, an antigen distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400

PR Newswire news releases · 2026-11-17 20:00

証拠を見る
  • 企業開示PR Newswire news releases2026-11-17 20:00
    Actinium announced HER3, an antigen distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400
    出典を見る
  • 企業開示PR Newswire news releases2026-11-17 20:00
    Actinium will present preclinical data demonstrating ATNM-400's activity across therapy-resistant breast cancer models, further supporting its potential across multiple solid tumor indications.
    出典を見る
事実根拠 1
expected operations funding through2027

Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.

PR Newswire news releases · 2026-11-17 20:00

証拠を見る
  • 企業開示PR Newswire news releases2026-11-17 20:00
    Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.
    出典を見る
事実根拠 1
cash and cash equivalents28.7 million

Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.

PR Newswire news releases · 2026-11-17 20:00

証拠を見る
  • 企業開示PR Newswire news releases2026-11-17 20:00
    Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.
    出典を見る
事実根拠 1
を使用Iomab-ACT

Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.

PR Newswire news releases · 2026-11-17 20:00

証拠を見る
  • 企業開示PR Newswire news releases2026-11-17 20:00
    Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.
    出典を見る

18 件中 1 から 6 件を表示

市場とバリュエーション

バリュエーションは Pro と Research で利用できます。

Pro で解放

監視するページを提案する

この企業について、料金、更新履歴、規約、採用など、見ておくべきページはありますか? ぜひ提案してください。提案はすべて人が確認します。追加したページはみなさん共通で監視し、続けて2回の取得が一致したときだけ変化として数えます。

サインインしてページを提案

利用できません: 企業シグナル · 財務 · 開示資料 · 拠点 · ガイダンス